Compare Stocks: XNCR, IONS, SYRE, and ALKS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$40.61 +1.2%	$45.93	$27.00 ▼ $55.67	$6.81B	0.32	2.62 million shs	1.63 million shs
IONS Ionis Pharmaceuticals	$45.28 +4.6%	$52.94	$42.63 ▼ $86.74	$7.52B	0.38	4.40 million shs	4.86 million shs
SYRE Spyre Therapeutics	$85.69 +7.2%	$94.15	$18.12 ▼ $110.18	$8.73B	3.1	1.60 million shs	1.12 million shs
XNCR Xencor	$24.63 +0.5%	$24.77	$10.38 ▼ $30.61	$1.83B	0.89	1.52 million shs	1.15 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-2.73%	-11.93%	-21.81%	+28.88%
IONS Ionis Pharmaceuticals	0.00%	+4.00%	-18.63%	-22.27%	-35.28%
SYRE Spyre Therapeutics	0.00%	-8.05%	-3.40%	-12.33%	+384.67%
XNCR Xencor	0.00%	-0.85%	+1.53%	+55.39%	+98.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$40.61 +1.2%	$45.93	$27.00 ▼ $55.67	$6.81B	0.32	2.62 million shs	1.63 million shs
IONS Ionis Pharmaceuticals	$45.28 +4.6%	$52.94	$42.63 ▼ $86.74	$7.52B	0.38	4.40 million shs	4.86 million shs
SYRE Spyre Therapeutics	$85.69 +7.2%	$94.15	$18.12 ▼ $110.18	$8.73B	3.1	1.60 million shs	1.12 million shs
XNCR Xencor	$24.63 +0.5%	$24.77	$10.38 ▼ $30.61	$1.83B	0.89	1.52 million shs	1.15 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-2.73%	-11.93%	-21.81%	+28.88%
IONS Ionis Pharmaceuticals	0.00%	+4.00%	-18.63%	-22.27%	-35.28%
SYRE Spyre Therapeutics	0.00%	-8.05%	-3.40%	-12.33%	+384.67%
XNCR Xencor	0.00%	-0.85%	+1.53%	+55.39%	+98.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.74	Moderate Buy	$54.47	34.13% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	97.00% Upside
SYRE Spyre Therapeutics	2.88	Moderate Buy	$110.40	28.84% Upside
XNCR Xencor	2.64	Moderate Buy	$34.00	38.04% Upside

Current Analyst Ratings Breakdown

Latest XNCR, IONS, SYRE, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/11/2026	SYRE Spyre Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$120.00
10/1/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00
10/1/2026	SYRE Spyre Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/30/2026	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
9/28/2026	XNCR Xencor	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00 ➝ $29.00
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$50.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$50.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
9/22/2026	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$56.00
9/22/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $61.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.62	$1.67 per share	24.25	$11.02 per share	3.69
IONS Ionis Pharmaceuticals	$944M	7.97	N/A	N/A	$3.02 per share	14.99
SYRE Spyre Therapeutics	$890K	9,811.99	N/A	N/A	$7.21 per share	11.88
XNCR Xencor	$125.58M	14.58	N/A	N/A	$8.90 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	106.87	169.21	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	11/4/2026 (Estimated)

Latest XNCR, IONS, SYRE, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.21	N/A	N/A	N/A	$183.13 million	N/A
11/4/2026	Q3 2026	XNCR Xencor	-$0.3837	N/A	N/A	N/A	$59.08 million	N/A
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.7778	N/A	N/A	N/A	N/A	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0788	N/A	N/A	N/A	$463.35 million	N/A
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
SYRE Spyre Therapeutics	N/A	18.53	18.53
XNCR Xencor	N/A	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
IONS Ionis Pharmaceuticals	93.86%
SYRE Spyre Therapeutics	80.39%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
IONS Ionis Pharmaceuticals	1.81%
SYRE Spyre Therapeutics	15.69%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
SYRE Spyre Therapeutics	112	101.91 million	85.92 million	Optionable
XNCR Xencor	260	74.35 million	70.58 million	Optionable

XNCR, IONS, SYRE, and ALKS Headlines

Recent News About These Companies

Xencor: Better Funding For Obexelimab

October 7, 2026 | seekingalpha.com

Xencor stock fell 4.96 percent as targets diverged

October 7, 2026 | ad-hoc-news.deA

Xencor (NASDAQ:XNCR) Stock Picked Up by Analysts at Wells Fargo & Company

October 2, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and IQVIA Holdings (IQV)

September 30, 2026 | theglobeandmail.com

Wells Fargo & Company Initiates Coverage on Xencor (NASDAQ:XNCR)

September 30, 2026 | marketbeat.com

Xencor stock falls 3.52 percent as Truist lifts its target

September 29, 2026 | ad-hoc-news.deA

Xencor (NASDAQ:XNCR) Shares Climb 4.6% - Should You Buy?

September 28, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Earns Buy Rating from Truist Financial

September 28, 2026 | marketbeat.com

Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE

September 28, 2026 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 26, 2026 | marketbeat.com

Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says

September 25, 2026 | finance.yahoo.com

Xencor (NASDAQ:XNCR) Price Target Raised to $26.00

September 21, 2026 | marketbeat.com

BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating

September 21, 2026 | marketscreener.comM

Xencor stock steadies after recent earnings, analysts watch pipeline progress

September 19, 2026 | ad-hoc-news.deA

Hsbc Holdings PLC Has $2.08 Million Position in Xencor, Inc. $XNCR

September 12, 2026 | marketbeat.com

Xencor to Present at the 2026 Cantor Global Healthcare Conference

September 2, 2026 | finance.yahoo.com

Xencor (NASDAQ:XNCR) Hits A Fresh High: What Comes Next?

August 18, 2026 | kalkinemedia.comK

Xencor, Inc. (XNCR) Stock Major Holders - Yahoo Finance

August 12, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Alpha Teknova (TKNO) and Solventum Corporation (SOLV)

August 11, 2026 | theglobeandmail.com

Xencor: Q2 Earnings Snapshot

August 7, 2026 | sfgate.com

RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)

August 7, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XNCR, IONS, SYRE, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

$40.61 +0.50 (+1.25%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$40.64 +0.03 (+0.07%)

As of 10/9/2026 07:30 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Ionis Pharmaceuticals NASDAQ:IONS

$45.28 +1.98 (+4.57%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$45.08 -0.20 (-0.44%)

As of 10/9/2026 07:55 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Spyre Therapeutics NASDAQ:SYRE

$85.69 +5.79 (+7.25%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$85.76 +0.06 (+0.08%)

As of 10/9/2026 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Xencor NASDAQ:XNCR

$24.63 +0.13 (+0.53%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$24.64 +0.01 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XNCR, IONS, SYRE, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XNCR, IONS, SYRE, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XNCR, IONS, SYRE, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XNCR, IONS, SYRE, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XNCR, IONS, SYRE, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XNCR, IONS, SYRE, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XNCR, IONS, SYRE, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XNCR, IONS, SYRE, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools